ReviewJournal of fungi (Basel, Switzerland)2024
Amphotericin B in the Era of New Antifungals: Where Will It Stand?
Review in Journal of fungi (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Cerebral venous thrombosis in non-bacterial infections: a systematic review.BMC neurology · 2026Pooled it
- Chronic Infections as Catalysts for Melanoma Aggressiveness: Insights into Tumour Microenvironment Modulation.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Algorithm-based approach to the management of rhino-maxillary mucormycosis: part II of a two-part study.BMC oral health · 2026Article
- Development of Oral pH-Sensitive Eudragit L100-FunctionalizedACS omega · 2026Article
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- In vitro evaluation of Curcuma longa extract for antifungal, antibiofilm, and synergistic activity against Candida spp.Scientific reports · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Liposomal Methylglyoxal Targets Virulence and Intracellular Persistence to Overcome Amphotericin B Resistance inInternational journal of molecular sciences · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- The KW18 peptide acts as a dual antimicrobial and immunomodulatory therapeutic candidate in the context of antimicrobial resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Boron's Double Edge-Antibiotics, Toxins, and the Fine Line Between Them.Molecules (Basel, Switzerland) · 2026Review
- Antifungal Activity of Four Medium-Chain Fatty Acids and γ-Undecalactone AgainstCurrent issues in molecular biology · 2026Article
- Evaluation of Antimicrobials Incorporated into Artificial Saliva: Analysis AgainstJournal of functional biomaterials · 2026Article
- Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease.Drug design, development and therapy · 2026Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Article
- Review
- Repurposing Acetylcholinesterase Inhibitors for Leishmaniasis: Donepezil Hydrochloride and Related Compounds Against the American Tegumentary Form.Antibiotics (Basel, Switzerland) · 2025Article
- Comparative Evaluation of Temperature, Bottle Type, and Amphotericin B on Fungal Detection in Corneal Preservation Media Using the BACT/ALERT SystemMicroorganisms · 2025Article
- Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistantIranian journal of microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphotericin B (AmB) has long stood as a cornerstone in the treatment of invasive fungal infections (IFIs), especially among immunocompromised patients. However, the landscape of antifungal therapy is evolving. New antifungal agents, boasting novel mechanisms of action and better safety profiles, are entering the scene, presenting alternatives to AmB's traditional dominance. This shift, prompted by an increase in the incidence of IFIs, the growing demographic of immunocompromised individuals, and changing patterns of fungal resistance, underscores the continuous need for effective treatments. Despite these challenges, AmB's broad efficacy and low resistance rates maintain its essential status in antifungal therapy. Innovations in AmB formulations, such as lipid complexes and liposomal delivery systems, have significantly mitigated its notorious nephrotoxicity and infusion-related reactions, thereby enhancing its clinical utility. Moreover, AmB's efficacy in treating severe and rare fungal infections and its pivotal role as prophylaxis in high-risk settings highlight its value and ongoing relevance. This review examines AmB's standing amidst the ever-changing antifungal landscape, focusing on its enduring significance in current clinical practice and exploring its potential future therapeutic adaptations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.